These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30023989)

  • 1. The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.
    Blum D; Chern Y; Domenici MR; Buée L; Lin CY; Rea W; Ferré S; Popoli P
    J Caffeine Adenosine Res; 2018 Jun; 8(2):43-58. PubMed ID: 30023989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine receptors and Huntington's disease.
    Lee CF; Chern Y
    Int Rev Neurobiol; 2014; 119():195-232. PubMed ID: 25175968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.
    Villar-Menéndez I; Blanch M; Tyebji S; Pereira-Veiga T; Albasanz JL; Martín M; Ferrer I; Pérez-Navarro E; Barrachina M
    Neuromolecular Med; 2013 Jun; 15(2):295-309. PubMed ID: 23385980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics.
    Blum D; Hourez R; Galas MC; Popoli P; Schiffmann SN
    Lancet Neurol; 2003 Jun; 2(6):366-74. PubMed ID: 12849153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.
    Popoli P; Blum D; Domenici MR; Burnouf S; Chern Y
    Curr Pharm Des; 2008; 14(15):1500-11. PubMed ID: 18537673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
    Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
    Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
    Kao YH; Lin MS; Chen CM; Wu YR; Chen HM; Lai HL; Chern Y; Lin CJ
    Hum Mol Genet; 2017 Feb; 26(3):467-478. PubMed ID: 28069792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of adenosine signaling reverses 3-nitropropionic acid-induced bradykinesia and memory impairment in adult zebrafish.
    Wiprich MT; Altenhofen S; Gusso D; Vasques RDR; Zanandrea R; Kist LW; Bogo MR; Bonan CD
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110602. PubMed ID: 35843370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington's disease.
    Chen CY; Chou FY; Chang YG; Ho CJ; Wu KC; Hsu CL; Chern Y; Lin CJ
    Neurobiol Dis; 2023 Feb; 177():106004. PubMed ID: 36669543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.
    Simmons DA
    J Huntingtons Dis; 2017; 6(4):303-325. PubMed ID: 29254102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new drug design targeting the adenosinergic system for Huntington's disease.
    Huang NK; Lin JH; Lin JT; Lin CI; Liu EM; Lin CJ; Chen WP; Shen YC; Chen HM; Chen JB; Lai HL; Yang CW; Chiang MC; Wu YS; Chang C; Chen JF; Fang JM; Lin YL; Chern Y
    PLoS One; 2011; 6(6):e20934. PubMed ID: 21713039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals.
    Landwehrmeyer GB; McNeil SM; Dure LS; Ge P; Aizawa H; Huang Q; Ambrose CM; Duyao MP; Bird ED; Bonilla E
    Ann Neurol; 1995 Feb; 37(2):218-30. PubMed ID: 7847863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.
    Martire A; Pepponi R; Domenici MR; Ferrante A; Chiodi V; Popoli P
    J Neurochem; 2013 Apr; 125(2):225-35. PubMed ID: 23363456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
    Guitart X; Bonaventura J; Rea W; Orrú M; Cellai L; Dettori I; Pedata F; Brugarolas M; Cortés A; Casadó V; Chang CP; Narayanan M; Chern Y; Ferré S
    Neurobiol Dis; 2016 Dec; 96():47-53. PubMed ID: 27567601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
    Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
    J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP46A1 protects against NMDA-mediated excitotoxicity in Huntington's disease: Analysis of lipid raft content.
    Boussicault L; Kacher R; Lamazière A; Vanhoutte P; Caboche J; Betuing S; Potier MC
    Biochimie; 2018 Oct; 153():70-79. PubMed ID: 30107216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease.
    Tyebji S; Saavedra A; Canas PM; Pliassova A; Delgado-García JM; Alberch J; Cunha RA; Gruart A; Pérez-Navarro E
    Neurobiol Dis; 2015 Feb; 74():41-57. PubMed ID: 25449908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.
    Wiprich MT; Bonan CD
    Front Neurosci; 2021; 15():657338. PubMed ID: 34276284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.